Pennyheaven Super 7 (2010)

Once again, our main criterion is growth: earnings, sales, and/or revenues must be increasing. The second criterion is profitability. All companies listed are currently profitable. Prices reflect close of business 12/31/09. Best of Luck!

1) Brekford Corp  BFDI (.15)
57,815,513 shares outstanding (s/o) as of 11/2/09
$1.06m cash; 86k debt
9-month sales up 16%
9-month net earnings (+ .01) v (- .03)
Market Cap – $8.67m

Brekford Corp. is a leading homeland technology service provider of fully integrated vehicle installation and rugged technology solutions geared towards mission critical operations. For more than a decade, the company has provided services to branches of the U.S. military, various federal entities and numerous security and public safety agencies. Brekford provides these agencies with an end-to-end suite of mobile products and services designed to streamline procurement and operations.

Brekford 360 Degree vehicle solutions provides complete vehicle upfitting, mobile data and video solutions including municipal financing and leasing services for agencies. The 360 Degree vehicle solutions approach provides customers with a one stop upfitting, cutting edge technology and installation service.

For more Company information, please see website:

2) Biostar Pharmaceuticals, Inc.  BSPM (4.45)
23,240,899 s/o as of 11/10/09
$2.45m cash; 0 debt
9-month net sales up 52%
9-month net earnings (+ .37) v (+ .18)
Market Cap – $103.43m

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company’s most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter (“OTC”) medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products, two prescription-based pharmaceuticals and thirteen nutrients. The Company has adopted international standards and is in the process of applying for two patents.

3) Destiny Media Technologies  DSNY (.49)
52,059,647 s/o as of 11/26/09
$253k cash, 68k debt
Net income 2009 (+ .01) v (- .05) (2008)
Market Cap – $27.59m

From 10-K (11/30/2009)
Revenue continued to grow during our fourth quarter and was the highest in the Company’s history. Fourth quarter revenue was 77% higher than the same quarter in the prior year and more than 31% above the previous quarter in fiscal 2009. Total revenue for the quarter is $872,569 (third quarter fiscal 2009 – $665,829). Total revenue for the year was $2,560,447 (2008 – $1,578,888), an increase of approximately 62% over the fiscal 2008 year.

Destiny Media ( is the developer of the Play MPE® system ( which the recording industry uses to securely distribute new pre-release music through the internet to trusted recipients such as radio, media and VIP’s. Real time usage statistics are available at

4) Stellar Pharmaceuticals Inc  SLXCF (.98)
23,495,040 s/o as of 9/30/09
$1.91m cash; minimal debt
9-month net revenues up 61%
9-month net earnings (+ .01) v. (- .01)
Market Cap – $23.03m

Stellar Pharmaceuticals Inc has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology: NeoVisc, for the treatment of osteoarthritis; and Uracyst, its patented technology for treatment of interstitial cystitis/painful bladder syndrome, an inflammatory disease of the urinary bladder wall. Stellar also has in-licensing agreement for the distribution and sale of NMP22 BladderChek, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

5) Superclick, Inc SPCK (.115)
45,312,251 s/o as of 8/31/09
$1.9m cash; 52k debt
9-month net revenue up 16%
9-month net (+ . 02) v. (+ .01)
Record quarterly revenues for the third quarter ending July 31, 2009
Market Cap – $5.21m

Superclick, Inc. through its wholly owned, Montreal-based subsidiary Superclick Networks, Inc., develops, manufactures, markets and supports the Superclick Internet Management System (SIMS(TM)), Monitoring and Management Application (MAMA(TM)) and Media Distribution System (MDS(TM)) in worldwide hospitality, conference center and event, multi-tenant unit (MTU) and university markets. Current clients include MTU residences and Candlewood Suites, Crowne Plaza, Fairmont Hotels and Resorts, Four Seasons Hotels and Resorts, Four Points by Sheraton, InterContinental Hotels Group PLC, Hilton, Holiday Inn, Holiday Inn Express, Hampton Inn, Mandarin Oriental Hotel Group Marriott, Novotel, Radisson, Sheraton, Westin and Wyndham hotels in Canada, the Caribbean and the United States.

6) Technical Communications TCCO (4.10)
1.47m s/o
5.42m cash; 0 debt
Market Cap – $6.02m

For the year ended September 26, 2009, the Company reported revenue of $7,752,000 and net income of $943,000, or $0.65 per share, as compared to revenue of $6,852,000 and net income of $1,061,000, or $0.75 per share, for fiscal 2008. For the quarter ended September 26, 2009, the Company reported net income of $235,000, or $0.16 per share, on revenue of $1,765,000, as compared to a net loss of $(87,000), or $(0.06) per share, on revenue of $1,204,000 for the quarter ended September 27, 2008.

TCC designs, manufactures, and supports superior grade secure communications systems that protect highly sensitive information transmitted over a wide range of data, voice and fax networks. TCC’s security solutions protect information privacy on every continent in over 110 countries. Government agencies, militaries, financial institutions, telecommunications carriers and multinational corporations worldwide rely on TCC to protect their communications networks.

Web Site:

7) Tikcro Technologies TIKRF (.92)
~ 8.42m s/o
$7.4m cash; 0 debt
Market Cap – $7.75m

Tikcro Technologies Reports 2009 Third Quarter Results

Net income for the third quarter was $590,000 or $0.07 per diluted share. Net income for the nine months ended September 30, 2009 was $4.7 million or $0.56 per diluted share. Results for the third quarter included financial income of $692,000 primarily from to the valuation of Tikcro’s holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. Tikcro holds 36% of BioCancell, taking into account the conversion of a convertible note and exercise of warrants, and 27% on a fully diluted basis. Shares of BioCancell are traded on the Tel Aviv Stock Exchange.

Tikcro Technologies has holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. BioCancell is conducting the following clinical trials in Israel and in the U.S. using its leading drug, BC-819:  – Phase IIb clinical trial for the treatment of superficial bladder carcinoma   cancer – Phase I/IIa clinical trial for the treatment of ovarian cancer – Phase I/IIa clinical trial for the treatment of pancreatic cancer.

Please be advised that nothing within this notice shall constitute a solicitation or an offer to buy or sell any security mentioned herein. All statements made are our express opinion only and should be treated as such. Nothing within this notice should be considered personalized investment advice. is neither a registered investment advisor nor affiliated with any broker or dealer. Any investments in stocks recommended in this notice should be made only after consulting with your investment advisor and only after reviewing the financial statements of the company. We reserve the right to trade in and out of these stocks at will, before, during, and/or after publication. We have not been compensated by any individual or company and we do not accept any paid promotion. Please do your own DD and trade only what is right for you.